Evaluation of the Effect of a Speech Detection Tool on the Improvement of Phonation in Neuromuscular Patients Dependent on Mechanical Ventilation

NCT ID: NCT03504514

Last Updated: 2019-11-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

28 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-11-06

Study Completion Date

2020-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Ventilation is a major treatment of respiratory failure due to neuromuscular disorders. First line treatment is noninvasive ventilation (NIV) but in some situations, especially in case of NIV inefficiency, invasive ventilation with tracheostomy (IVT) may be required. In both situations, patients may become dependent on ventilatory support with the disease evolution. Ventilation then can interfere speech and the quality of communication of the patients. Modification of the ventilation parameters may result in improved speech quality (for example, positive expiratory pressure (PEP) while not necessary for ventilation quality can dramatically improve speech in tracheostomized patients). Therefore, it would be of interest to allow patients to benefit from these specific parameters when they need to speak without maintaining them when patients are not speaking. We want to evaluate a specific ventilator feature which can detect speech and switch to specific ventilation parameters adapted for speech We believe that this feature will improve significantly speech quality in patients dependant either on NIV or IVT.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Nowadays, the first line treatment of chronic respiratory failure in neuromuscular disorder is non invasive ventilation (NIV). However, while NIV can compensate the respiratory disability and significantly delays significantly the necessity for invasive ventilation with a tracheostomy (IVT), it is used for significant periods of time during daytime in patients with severe respiratory failure and can therefore interfere with patients' speech. Moreover, if NIV becomes inefficient, IVT may be required to pursue ventilatory support to treat the respiratory failure; tracheostomy also interferes with phonation and specific adaptations are necessary to optimize phonation and speech quality.

Adaptation of ventilation parameters (mainly triggering sensitivity and use of positive expiratory pressure (PEP)) can significantly improve speech quality and therefore ventilated patients' communication. These adapted parameters are not strictly necessary for ventilation outside of speaking periods. It would be of interest to be able to use them exclusively during speech. In neuromuscular patients, the major motor disability constitutes a challenge as most patients are unable to use themselves the controls of their ventilator (and to potentially switch to a speech adapted ventilation program). We want to evaluate a device able to automatically detect speech and to transitorily switch from the patient's usual ventilation parameters to speech specific parameters set to optimize phonation quality.

Specific adaptations differs between NIV or IVT, therefore we will evaluation two groups of ventilation dependent patients divided according to their ventilation mode.

We believe that this device may improve the speech of NIV patients as well as IVT patients. Patients would benefit from an appropriate ventilator support without any ventilation desynchronization during speech. Speech would be more fluent and natural which would result in improved communication.

Objectives The main objective of this study is to demonstrate that phonation is improved by the use of a device allowing the transitory switch to specific speech parameters of ventilation in neuromuscular ventilator dependent patient whether during NIV or during IMT.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neuromuscular Diseases Mechanical Ventilation Speech

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

monocentric, open, randomized, crossover study
Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Conventional mechanical ventilation

Conventional mechanical ventilation, with patient ventilator usual parameters

Group Type NO_INTERVENTION

No interventions assigned to this group

Adapted mechanical ventilation

Mechanical ventilation with parameters specifically modified to improve speech the effect is evaluated with speech trials during different ventilation conditions

Group Type EXPERIMENTAL

speech trials during different ventilation conditions

Intervention Type DEVICE

ventilator parameters are modified

speech trial

Intervention Type OTHER

reading duration, vocal flow, intelligibility and voice quality will be evaluated during speech

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

speech trials during different ventilation conditions

ventilator parameters are modified

Intervention Type DEVICE

speech trial

reading duration, vocal flow, intelligibility and voice quality will be evaluated during speech

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* adult patients (age \> or equal to 18)
* Neuromuscular patients with a restrictive respiratory failure without major bulbar involvement.
* Adult patient.
* Ventilator dependancy= ventilation duration of 16h/day or more either with NIV or IMT
* Leak ventilation for IMT patients
* Respiratory autonomy of at leat 1h per day
* Usual ventilation mode : assist control mode (either pressure or volume controlled mode) ou spontaneous breathing mode with target volume
* Stable hemodynamic state
* Signed informed consent

Exclusion Criteria

* Refusal to participate
* Use of cuffed tracheostomy tube
* Inability to read
* Pregnancy
* Protected adults
* Acute respiratory failure
* Hemodynamic instability
* not registered with the social security system
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Centre d'Investigation Clinique et Technologique 805

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Hélène Prigent, MD PhD

Role: PRINCIPAL_INVESTIGATOR

Raymond Poincaré Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Raymond Poincaré hospital

Garches, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Hélène Prigent, MD PhD

Role: CONTACT

0033147107911

Isabelle BOSSARD

Role: CONTACT

0033147104615

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Hélène PRIGENT, MD PhD

Role: primary

0033147107911

Isabelle BOSSARD

Role: backup

0033147104615

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2017-A00109-44

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.